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Graphical Abstract 
Abstract: 
The aim of this work was to investigate the efficient targeting and delivery of indometacin 
(IND), as a model anti-inflammatory drug to the colon for treatment of inflammatory bowel 
disease. We prepared fast disintegrating tablets (FDT) containing IND encapsulated within 
poly(glycerol-adipate-co-ɷ-pentadecalactone), PGA-co-PDL, microparticles and coated with 
Eudragit L100-55 at different ratios (1:1.5, 1:1, 1:0.5). Microparticles encapsulated with IND 
were prepared using an o/w single emulsion solvent evaporation technique and coated with 
Eudragit L-100-55 via spray drying. The produced coated microparticles (PGA-co-PDL-
IND/Eudragit) were formulated into optimised FTD using a single station press. The loading, 
in vitro release, permeability and transport of IND from PGA-co-PDL-IND/Eudragit 
microparticles was studied in Caco-2 cell lines. IND was efficiently encapsulated (570.15±4.2 
µg/mg) within the PGA-co-PDL microparticles. In vitro release of PGA-co-PDL-IND/Eudragit 
microparticles (1:1.5) showed significantly (p<0.05, ANOVA/Tukey) lower release of IND 
13.70±1.6 and 56.46±3.8 % compared with 1:1 (89.61±2.5, 80.13±2.6 %) and 1:0.5 (39.46±0.9 
& 43.38±3.12) after 3 and 43 h at pH 5.5 and 6.8, respectively. The permeability and transport 
studies indicated IND released from PGA-co-PDL-IND/Eudragit microparticles had a lower 
permeability coefficient of 13.95±0.68x10-6cm/s compared to free IND 23.06±3.56x10-6cm/s. 
These results indicate the possibility of targeting anti-inflammatory drugs to the colon using 
FDTs containing microparticles coated with Eudragit. 
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1 Introduction 
Drug targeting to specific regions of the gastrointestinal tract is still under focus of 
extensive research to achieve an effective and patient attractive formulation with an enhanced 
therapeutic effect. Moreover, it is challenging to design a drug delivery system, DDS, able to 
deliver drugs to the specific site of action and at the right period of time (Mishra et al., 2010). 
One of the most important diseases which affect the gastro-intestinal tract, GIT, is the 
inflammatory bowel disease (IBD), which is an inflammatory condition of the colon and small 
intestine such as Crohn's disease (CD) and ulcerative colitis (UC) (Cosnes et al., 2011). People 
suffering from IBD require the frequent intake of anti-inflammatory drugs at high doses, which 
are associated with significant adverse effects (Abdellatif et al., 2016; Santino et al., 2017).  
Therefore, different methods and approaches have been studied to develop oral colon DDS, 
among them series of enteric soluble cellulose polymers and methacrylic acid co-polymers 
have been investigated (Donini et al., 2002; Silva et al., 2009; Wang et al., 2010). However, 
targeting to the colon using enteric coated formulations has many drawbacks such as dose 
dumping in the small intestine leading to intestinal damage as well as the frequent 
administration which reduces patient compliance (Hao et al., 2014). Moreover, in many cases 
there is a lower efficiency due to diarrhoea, a symptom of IBD that enhances drug elimination 
and affects its release time (Lamprecht et al., 2004). DDS, incorporating microparticles and 
nanoparticles could enhance the drug bioavailability compared to matrix systems, and thus 
reduce the drug dose and side effects as well as the potential of any systemic toxicity. Previous 
attempts to produce microparticles with enteric and extended release pattern using emulsion 
solvent evaporation have been demonstrated (Alhnan et al., 2011). In addition, they showed 
better in vivo performance, less irritation and reproducible drug release compared with single 
unit systems (Beloqui et al., 2016; Duan et al., 2016; Rashid et al., 2016; Youshia and 
Lamprecht, 2016). Furthermore, these systems are capable of passing through the GIT easily 
due to their small particle size, leading to less inter-intra-subject variability.  
The techniques used to deliver drugs to the colon are reliant on the variation of the pH 
through the GIT (Makhlof et al., 2009; McConnell et al., 2008). One of the most commonly 
used pH-dependent polymers for colon delivery is the methacrylic acid co-polymers, Eudragit 
L100-55, which is widely used for different oral colon drug delivery targeted dosage forms 
(tablet coating, tablet matrix, microspheres and nanoparticles) (Chickpetty et al., 2011; 
Jelvehgari et al., 2010a; Moustafine et al., 2006; Oosegi et al., 2008; Zakeri-Milani et al., 2009). 
Furthermore, it is used to control drug release within the pH 4 to 6 range, hence can be used to 
deliver drugs in the treatment of IBD due to the extremely acidic colon environment (Friend, 
2005; Sasaki et al., 1997). In addition it has mucoadhesive properties (Wang and Zhang, 2012; 
Yamanaka and Leong, 2008), which ensures the coated particles remain at the site of action 
and are not affected by diarrhoea associated with IBD. 
Poly(glycerol-adipate-co-ɷ-pentadecalactone), PGA-co-PDL, is biodegradable 
polyester studied as a carrier for small and large molecular weight compounds ((Tawfeek et 
al., 2014; Alfagih et al., 2015; Kunda et al., 2015a; Kunda et al., 2015b; Kunda et al., 2015c; 
Tawfeek et al., 2011a; Tawfeek et al., 2013)). Fast disintegrating tablets, FDTs, or 
orodispersible tablets are intended for administration to patients with difficulty in swallowing, 
such as the elderly and paediatric patients. Hence, FDTs have a rapid disintegration, drug 
release, achieve improved bioavailability and fast absorption (El Maghraby and Elsergany, 
2014). Moreover, FDTs containing multiparticulate drug delivery systems, such as 
nanoparticles or microparticles have been studied for oral delivery of drugs, such as  
acetazolamide and scopolamine (Li et al., 2011; Preeti et al., 2014) and prednisolone (Chen et 
al., 2015). 
The aim of the current work was to study the applicability of novel formulation design to 
deliver indometacin (IND) as a model anti-inflammatory drug for the treatment of IBD. This 
was performed through encapsulating IND within PGA-co-PDL microparticles (MPs) coated 
with Eudragit L100-55 (PGA-co-PDL/Eudragit MPs). The Eudragit L100-55 will begin to 
dissolve at pH ≥ 5.5, and the PGA-co-PDL acts as a controlling matrix for sustained release of 
IND. Such design will control and extend the IND release at the site of inflammation. Finally, 
the prepared PGA-co-PDL/Eudragit MPs were incorporated into fast disintegrating tablets to 
facilitate their administration to patients i.e. elderly and paediatrics.  
2 Materials and Methods 
2.1 Materials 
Indometacin (γ form) was purchased from Sigma-Aldrich (Cairo, Egypt). Sodium starch 
glycolate, SSG, magnesium stearate, cross-linked sodium carboxymethyl cellulose, Ac-Di-Sol, 
Transwell (Corning) semi-permeable membrane supports (12 well, 1.12 cm2, 0.4 μm pore size) 
were obtained from Fisher Scientific, UK. PGA-co-PDL (15 KDa) was synthetized in our lab 
(LJMU, UK). Eudragit L100-55 was obtained from Evonik, GmbH, Germany. Anhydrous 
lactose was obtained from DFE pharma. All other chemicals and reagents were used as 
received. 
2.2 Methods 
2.2.1 Preparation of Eudragit coated PGA-co-PDL microparticles  
PGA-co-PDL MPs encapsulated with IND non-coated and coated with Eudragit L100-55 
(PGA-co-PDL/Eudragit) were prepared by single emulsion/solvent evaporation technique 
followed by spray drying. PGA-co-PDL MPs were prepared as previously reported (Tawfeek 
et al., 2011a). Briefly, 50 mg IND and 450 mg PGA-co-PDL (15 KDa) was dissolved in 5 ml 
dichloromethane (DCM). The organic layer was emulsified in 10 ml water containing 0.1% 
polyvinyl alcohol (PVA) using a IKA yellow line DI 25 basic homogeniser at 8000 rpm for 
40-50 s. This o/w emulsion was left to mix with a Silverson L4 RT mixer at 2000 rpm for 3 h 
to allow for DCM evaporation under room temperature. The particles obtained were collected 
by centrifugation (EBA 20, Hettich) at 6000 x g for 10 min at room temperature and washed 
with PBS buffer and centrifuged again. PGA-co-PDL/Eudragit MPs were prepared by 
dissolving the calculated amounts of Eudragit L100-55 (1:0.5, 1:1 and 1:1.5 PGA-co-PDL: 
Eudragit, wt/wt ratio) in 20 ml PBS solution with pH value of 7.0±0.2. PGA-co-PDL MPs were 
suspended in Eudragit solution, mixed for 2 mins, and spray dried utilizing a mini-spray dryer 
(Büchi, B-290 Flawil, Switzerland) according to previous method (Tawfeek, 2013). The dry 
particles (PGA-co-PDL/Eudragit) were separated from the air stream using a high-performance 
cyclone (Büchi Labortechnik), and the dry particles were collected and stored in desiccator 
until further use. Spray dried particles were also prepared using PGA-co-PDL MPs alone.  
2.3 Characterisation of PGA-co-PDL/Eudragit microparticles 
2.3.1 Yield, Encapsulation efficiency and IND loading 
Spray dried PGA-co-PDL/Eudragit MPs yields were quantified as the percentage mass 
obtained compared with the anticipated total powder yields (n=3). The encapsulation efficiency 
of IND loaded PGA-co-PDL/Eudragit MPs (n=3) were obtained by dissolving the particles in 
2 ml DCM under mixing for 3 h followed by HPLC analysis. The chromatographic conditions 
were as follows: HPLC system Agilent 1100 series (Santa Clara, CA, USA) equipped with a 
column (Aeris 3.6 μm C4 200A Wide Pore 4.6 mm i.d. × 150 mm length), security cartridge 
of the same material (Phenomenex, UK); mobile phase was composed methanol: water 75:25% 
containing 0.2% ortho-phosphoric acid. The flow rate was adjusted to 1.5 ml/min; injection 
volume of 100 μl; temperature 23 °C; UV detection at λmax of 372 nm. IND calibration curve 
was prepared by accurate dilution of a previously prepared stock solution (1 mg/ml) in HPLC 
water and PBS (pH 7.4) to obtain the following concentrations: 0.5, 1, 2.5, 5, 7.5, 10, 15, 20, 
25, 50, 70 and 100 μg/ml of IND (n=9, R2=0.998). PGA-co-PDL and Eudragit L100-55 did 
not interfere with the UV absorption of IND. Moreover, IND loading (µg/mg PGA-co-PDL) 
was also determined using equation 2. 
 
Encapsulation efficiency (%) =
𝐴𝑐𝑡𝑢𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐼𝑁𝐷 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
𝑇ℎ𝑒𝑜𝑟𝑖𝑡𝑖𝑐𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐼𝑁𝐷 𝑎𝑑𝑑𝑒𝑑
  x 100          (1)   
IND loading (µg/mg polymer) = 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝐼𝑁𝐷 (µ𝑔)
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑃𝐺𝐴−𝑐𝑜−𝑃𝐷𝐿 (𝑚𝑔)
        (2) 
2.3.2 Powder X-ray diffraction 
Powder X-ray diffraction (PXRD) patterns were determined using a RigakuMiniflex X-ray 
diffractometer. Samples were finely ground and packed into an aluminium sample holder. 
Patterns were collected between 5° and 50° 2θ, at increments of 0.02° 2θ, scanning speed 
2°min-1, voltage 30 KV, current 15 mA using CuKα (1.54 Ǻ) radiation. 
2.3.3 Differential scanning calorimetry 
Differential scanning calorimetry thermograms were obtained using a Perkin Elmer DSC 8000 
with Intracooler 2 cooling accessory and Pyris v. 10.1.0.0420 software (Seer Green, 
Buckinghamshire, UK). The furnace temperature was calibrated using the Perkin Elmer 
supplied standard reference materials Indium (m.p. = 156.60 °C) and zinc (m.p. = 419.47 °C). 
Samples, 3–5 mg, were accurately weighed onto aluminium pans and sealed prior to heating at 
a constant heat rate of 20 °C min−1 in a nitrogen atmosphere over a temperature range of 25 °C–
250 °C. 
2.3.4 Particles Morphology 
PGA-co-PDL and PGA-co-PDL/Eudragit MPs were visualised by scanning electron 
microscopy (FEI–Inspect S Low VAC Scanning Electron Microscope). A suspension of 
particles in water was deposited on 13 mm aluminium stubs layered with a sticky conductive 
carbon tab and air-dried. An atomic layer of gold was deposited onto the particle containing 
stubs using an EmiTech K 550X Gold Sputter Coater, 25 mA for 3 min.  
2.3.5 In vitro release 
In vitro release of IND from PGA-co-PDL and PGA-co-PDL/Eudragit MPs at different weight 
ratios was performed in 0.1 N HCl, (pH 1.2) for 2 h, pH 5.5 for 3 h followed by pH 6.8 for the 
remainder of 48 h at 37 ± 0.5 °C using an automated Varian VK 7000 dissolution tester. The 
in vitro release was done according to the pH shift method to mimic the in vivo conditions 
using 0.2 M tribasic sodium phosphate (Hosny, 1996). Samples (5 mL) were removed from the 
dissolution vessels at specified time points and replaced with fresh buffer. The IND contents 
in the collected samples were measured using a UV spectrophotometer (Perkin Elmer) at λmax 
of 372 nm. 
2.4 Preparation and optimization of FDTs 
FDTs were prepared using two different superdisintegrants namely; cros-carmellose, Ac-Di-
Sol and sodium starch glycolate, SSG, at three different concentrations (5, 8 and 12% weight 
per total tablet weight). Briefly, the superdisintegrant and the diluent, lactose, were mixed for 
15 min using a turbula mixer (W.A. Bachofen, Switzerland) and subsequently with 1% (w/w) 
lubricant, magnesium stearate, for another 5 min. Tablets were compressed using a single-
station tablet Riva minipress at different compression forces 5, 10 and 15 KN and 
superdisintegrant concentrations as indicated in Table 1. The composition of the different 
prepared blank FDTs tablets is shown in Table 2. 
The prepared FDTs were characterised and optimised in terms of weight uniformity and in 
vitro disintegration (USP pharmacopeia 2008). Moreover, the crushing strengths F (KN) were 
determined using a model 6D tablet tester (Dr.Schleuniger, Germany) and the wettability test 
was performed as previously reported (Jung et al., 2012). In addition, the effect of addition of 
PGA-co-PDL and PGA-co-PDL/Eudragit MPs (10 %w/w of total tablet weight; 20 mg MPs 
containing 11.4 mg IND/tablet) on the crushing strength, wettability and the in vitro 
disintegration time of FDTs containing the optimum concentrations of SSG, 8 and 12% and 
compressed at 5 KN was also investigated and compared with blank FDTs. 
2.5 Permeability and transport study 
The permeability and transport study of IND from the prepared PGA-co-PDL/Eudragit MPs 
were studied in Caco-2 cell lines, grown on 12 well transwell semi-permeable membrane 
supports (1.12 cm2, 0.4 μm pore size) for 21 days, using DMEM media. Permeability study 
was performed over 6 h at different time points of 30, 60, 120, 180, 240 and 360 mins (n=3). 
The transepithelial electrical resistance, TEER, values for each well were taken at t=0 and 
t=360 mins to monitor cell integrity over the experimental period. A positive control (IND 
alone), treatment 1 (IND loaded PGA-co-PDL/Eudragit, 1:1.5 wt ratio, MPs suspension) and 
treatment 4 (IND loaded PGA-co-PDL MPs emulsion) were applied to the apical (donor) side 
of the cells (500 µL) and samples taken at the time points aforementioned. In addition, negative 
control treatment 2 (PGA-co-PDL /Eudragit, 1:1.5 wt ratio, MPs suspension) and treatment 3 
(PGA-co-PDL MPs emulsion) were sampled at t=360 and TEER values measured at t=0 and 
t=360 (n=3). 1.5 ml DMEM was added to the basolateral (acceptor) side of each well. IND 
alone was analysed and found to be 26.5 µg/ml IND, and treatment 1 and 4 were adjusted to 
give same concentration, based on the drug loading. The apical samples (100 µl) from each 
well were taken at t=0 to give the initial apical concentration and a final apical sample was 
taken at t=360 (100 µl). Basolateral samples (200 µl) were taken at the time points stated and 
immediately replaced with fresh DMEM to simulate sink conditions. Cumulative drug 
concentration was calculated from the data to account for this. Between sampling times points 
the cells were maintained in the incubator at 37 °C, 95% relative humidity and 5% CO2.  
 
Apparent permeability Papp (cm/s) was calculated according to the following equation: 
 
Papp = 
dQ
dt
. 
1
𝐴𝐶0
                                                            (3) 
 
Where; dQ/dt is the rate of appearance of the drug on the basolateral side, C0 is the initial 
concentration on the apical side and A is the surface area of the monolayer (cm2). 
2.6 Statistical analysis 
All statistical analysis was performed using Minitab® 16 Statistical Software. One-way analysis 
of variance (ANOVA) with the Tukey’s comparison was employed for comparing the 
formulations with each other. Statistically significant differences were assumed when p<0.05. 
All values are expressed as their mean ± standard deviation. 
3 Results and Discussions 
PGA-co-PDL/Eudragit MPs were produced to passively target the site of inflammation. This 
type of targeting based on the change in the physiological conditions of GIT will control the 
release of IND to the affected site especially with IBD patients. Moreover, the ulcerogenic and 
toxicity effects of IND will be minimised due to the encapsulation and coating processes and 
lower doses of IND used. 
3.1. PGA-co-PDL Microparticle preparations 
IND loaded PGA-co-PDL MPs were prepared via single emulsion (o/w) solvent evaporation 
technique. The prepared particles had an encapsulation efficiency and IND loading of 
63.16±3.5 % and 570.15±4.2 µg/mg particle; respectively. Therefore, IND dose in the final 
prepared tablets was 11.40 mg/tablet (20 mg particles per tablet). Similar studies have reported 
low IND loading in microspheres (5.7 µg/mg particles) used for colon targeting prepared via 
spray drying (Jain et al., 2014; Lee et al., 2004) and an electrospray technique with 
encapsulation efficiency of 35.39±1.63 %, whereas in our study we achieved an encapsulation 
efficiency of 63.16±3.5 %. (Arvind K Jain et al., 2014).  However, by increasing the amount 
of MPs in the FDTs a higher dose of IND would be obtained. For example, 40 mg MPs would 
contain approximately 24.0 mg IND that is similar to the conventional oral dose of IND (25 
mg /Tablet). Corrigan et al., showed that IND had an encapsulation efficiency of 65.2±0.6 % 
during preparation of PLGA nanoparticles by emulsion solvent evaporation technique due to 
leaking to the external aqueous medium (Corrigan and Li, 2009). Moreover, the degree of 
polymer crystallinity affects the encapsulation efficiency, hence drugs will be encapsulated in 
the amorphous region of the semi crystalline PGA-co-PDL (Kim et al., 2005; Tawfeek et al., 
2014). PGA-co-PDL/Eudragit MPs were efficiently prepared via spray drying with yields of 
(40.74±5.5, 43.33±4.3 and 55.7±6.7 % for 1:0.5; 1:1 and 1:1.5 PGA-co-PDL to Eudragit L100-
55 weight ratios; respectively), which was similar to our previous reports (Tawfeek et al., 
2011a). 
 
3.2. PGA-co-PDL Microparticle/Eudragit characterisation  
PXRD and Differential thermal analysis, DSC, techniques are used to study the crystal and 
thermal behaviour during processing and manufacturing. Furthermore, they provide 
information about the efficiency of coating of MPs as well as the degree of drug entrapment 
and crystallinity. The latter is an important consideration as the formation of drug crystals 
during microencapsulation process can have major impact on the property of final products 
(Alhnan and Basit, 2011; Nilkumhang et al., 2009). Furthermore, IND has 4 different 
polymorphs, γ-form (I), α-form (II), β-form (III) and δ-form (IV) (Dubbini et al., 2014). Hence, 
the polymorphic transitions should be considered during processing because different solid 
forms affect the physical properties e.g., solubility, physical stability, dissolution and 
bioavailability (Raina et al., 2014; Yoshinari et al., 2003; Zhang et al., 2004). PXRD showed 
characteristic peaks at 21.5° and 24.2°ɵ for PGA-co-PDL co-polymer (Fig.1; Trace A). 
Eudragit L100-55 has a characteristic amorphous structure (Shen et al., 2011), (Fig.1; Trace 
B). However, the non-coated PGA-co-PDL MPs loaded IND (Fig.1; Trace C) did not show the 
characteristic crystalline peaks of the IND γ-form ((Basavoju et al., 2008)), hence indicating 
efficient encapsulation of IND inside PGA-co-PDL MPs. However, the appearance of small 
peak at 27.28° ɵ was attributed to the formation of α-form of IND (Alhnan et al., 2010), which 
was confirmed using DSC (Fig. 2; Trace C). In addition, the reduced  PGA-co-PDL peaks 
intensities was attributed to the processing steps and was also reported in our previous study 
using PGA-co-PDL encapsulated α-chymotrypsin and with PLGA nanoparticles entrapped 
cyclosporine (Tawfeek et al., 2014; Wagh and Apar, 2014). PGA-co-PDL/Eudragit MPs loaded 
IND (1:1.5 wt/wt ratio) showed complete disappearance of PGA-co-PDL characteristic peaks 
(Fig.1; Trace D) which was attributed to the efficient coating of Eudragit L-100-55 around 
PGA-co-PDL particles. Similar behaviour was also observed by (Nadal et al., 2016) who used 
Eudragit L100 to coat MPs containing ferulic acid using spray drying method.  
DSC was performed to obtain more evidence about the coating and the thermal changes after 
spray drying and particles formulation (Fig. 2). The DSC results were in accordance with 
PXRD data. IND alone showed an endothermic crystalline peak at 160 °C due to drug melting 
which is characteristic for γ-form of IND (Basavoju et al., 2008) (Fig. 2; Trace A). PGA-co-
PDL polymer showed the characteristic melting broad peak at 57.12 °C, indicating the outlet 
temperature of spray dryer did not exceed the low melting of the polymer (Tawfeek et al., 
2011b). PGA-co-PDL showed an area under the endothermic peak of 269.04 mJ and heat of 
fusion (ΔH) of 60.59 J/gas as previously reported  (Tawfeek et al., 2014). Moreover, Eudragit 
L100-55 (Fig 2; Trace B) showed two very broad endothermic peaks at 70.14 and 209.84 °C. 
The first was due to side chain mobility (β-relaxation) and the second was due to the anhydride 
formation resulting from water evaporation during the heating process of the DSC scan leading 
to polymer decomposition. In addition, the glass transition temperature Tg which appeared at 
120 °C represented the main polymeric linear chain mobility (α-relaxation) (Assaf et al., 2013). 
Non-coated PGA-co-PDL MPs loaded IND showed similar melting peak as PGA-co-PDL 
polymer but with a lower area under the peak 50.04 mJ and ΔH of 27.80 J/g. In addition, it was 
noticed the complete disappearance of IND melting endotherm which possibly attributed to the 
complete entrapment of IND inside the PGA-co-PDL MPs (Fig. 2; Trace C). Meanwhile, the 
appearance of the small DSC hump at 155 °C was most likely attributed to the formation of the 
α-form of IND, which is in accordance with the PXRD results (Fig. 1; Trace C). Spray drying 
process reflects the thermal changes during the particles formation and processing (Tawfeek et 
al., 2011a). This could be observed with the PGA-co-PDL melting endotherm which became 
broader and coupled with decrease in both the area under the endothermic peak and the ΔH 
values (Fig. 2; Traces, D-F). Hence, increasing the amounts of Eudragit led to a higher 
reduction in the melting behaviour of PGA-co-PDL. 
 
3.3. Morphology and in vitro release of IND from PGA-co-PDL/Eudragit coated 
microparticles  
Scanning electron microscope (Fig. 3A) showed spherical, large and smooth nature of spray 
dried blank Eudragit particles. Spray dried IND loaded PGA-co-PDL MPs appeared spherical, 
small, aggregated with smooth surface showing corrugations (Fig. 3B) due to excessive build 
up of vapour pressure during spray drying process as previously reported (Tawfeek, 2013). A 
similar morphology was obtained with IND loaded PGA-co-PDL/Eudragit MPs (Fig. 3C-E).  
Furthermore, it was found that by increasing the amount of Eudragit, larger particles were 
observed with the surface morphology becoming smooth (Fig. 3E), indicating efficient coating 
of Eudragit around the PGA-co-PDL MPs. 
The in vitro release pattern (Fig. 4) was characterised by three phases, the lowest release phase 
was considered at pH 1.2. Non-coated PGA-co-PDL MPs released 31.91±1.7 % of IND after 
2 h, whereas, PGA-co-PDL/Eudragit MPs with different Eudragit ratios, 1:0.5; 1:1 and 1:1.5 
wt ratios, released 11.57±1.8, 4.53±0.85 and 2.43±0.75 % of IND at pH 1.2; respectively after 
the same period. Moreover, the burst release characterised by many biodegradable polymeric 
particles were not observed in the release of IND from Eudragit coated MPs, and this provided 
indication about the efficient coating and entrapment of IND inside the PGA-co-PDL/Eudragit 
MPs. Eudragit L100-55 a methacrylic acid – ethyl (1:1 ratio) acrylate co-polymer is widely 
used in the oral formulations for colon targeting either alone or in combination with Eudragit 
S100 (Asghar et al., 2009; Cetin et al., 2010; Jelvehgari et al., 2010b; Shen et al., 2011). 
Eudragit L100-55 prevented the premature release of IND in upper GIT, since it is a pH 
sensitive polymer having threshold pH value above 6.0. Increasing the pH from 1.2 to 5.5 and 
lastly to 6.8 led to 94.12±3.6 % release of IND from non-coated PGA-co-PDL MPs. The higher 
release of IND from non-coated MPs at acidic medium was attributed to the release of the α-
form of IND, which showed a reported higher dissolution rate compared to γ-form (Aceves-
Hernandez et al., 2009; Hulse et al., 2012). However, at higher pH values, IND diffused from 
the polymer matrix through the developed pores and channels showing a higher dissolution as 
reported from its acidic nature (Ali et al., 2016). PGA-co-PDL/Eudragit MPs 1:1.5 wt. ratio 
showed significantly (p<0.05, ANOVA/Tukey) lower release of IND 13.70±1.6 and 56.46±3.8 
% compared with 1:0.5 and 1:1 wt. ratios, 39.46±0.9 & 43.38±3.12 and 89.61±2.5, 80.13±2.6 
% after 3 and 43 h at pH 5.5 and 6.8, respectively. Furthermore, once the Eudragit dissolved, 
IND still needs to be released from PGA-co-PDL MPs and hence the formulation was able to 
maintain a sustained drug release. Similar results occurred from domperidone ODTs solid 
dispersions with Eudragit L100-55 when released in 0.1N HCL and pH 6.8 (Assaf et al., 2013). 
Hence, IND had a sustained release pattern from PGA-co-PDL/Eudragit MPs. As the pH 
increased the polymer solubility increased (Khan et al., 2000) resulting in an increase in IND 
release, meanwhile the release was greatly reduced at acidic pH. 
 
3.4. Optimizing the FDTs  
Optimum blank FDTs, without MPs, were selected based on investigating the effect of different 
concentrations of SSG or Ac-Di-Sol on the mechanical properties of FDTs. Blank FDTs, were 
prepared by direct compression technique at different compression forces ranging from 5 to 15 
KN. The prepared tablets had an average weight of 201±1.2, 198.5±0.7 and 202±2.5 mg for 
tablets containing 5, 8 and 10 % w/w of Ac-di-Sol and SSG, respectively. Fig. 5A & B showed 
that increasing the concentration of superdisintegrant, Ac-di-Sol or SSG, at the same force of 
compression led to a non-significant reduction in the crushing strength. This could be attributed 
to the interference of SSG or Ac-Di-Sol with the bonding property and/or the tablet porosity 
especially at higher superdisintegrant concentration. Also, higher superdisintegrant 
concentration led to a high hygroscopicity and porosity which facilitate water absorption 
resulting in a decreased tablet crushing strength (Fu et al., 2004).  
The FDTs compressed at 5 KN and containing Ac-Di-Sol showed significantly (p<0.05; 
ANOVA/Tukey) faster disintegration of 60.0±5.1, 65.0±7.5 and 50.0±6.5 s for 5, 8 and 12 % 
Ac-Di-Sol compared to the other compression forces (Fig. 5C). Meanwhile, a significantly 
(p<0.05, ANOVA/Tukey’s) faster disintegration time of 16.5±2.7 s was recorded from tablets 
containing 12% SSG compared to 5 and 8% SSG when compressed at 5 KN (Fig. 5C). Similar 
results have been reported by Tawfeek et al. (Tawfeek et al., 2014), using high concentrations 
of SSG in FDTs containing itopride HCl significantly decreased the in vitro disintegration time 
(Tawfeek et al., 2015). Hence, it could be concluded that formulation 12SSG-5CF was 
considered an optimum formulation in terms of in vitro disintegration time as stated in the 
optimum time for disintegration for orodispersible tablets in European Pharmacopeia 
(pharmacopoeia, 2002).  
Wetting is an important criterion in FDTs and is responsible for rapid disintegration (Abed et 
al., 2010; Sunada and Bi, 2002). The higher compression force produced tablets with stronger 
bonding of particles leading to a longer wetting time as shown with both Ac-Di-Sol and SSG 
tablets compressed at 15 KN. Hence, the fastest wetting time of 12.26±1.2 s was recorded in 
batch 12SSG-5CF, whereas the highest wetting time of 95.5±8.8 and 99.5±5.5 s which was 
observed in batches 8AC-15CF and 5SSG-15CF; respectively (Fig. 5D). These results were in 
accordance with the in vitro disintegration time data observed in above section. 
3.5. The effect of MPs addition to FDTs characteristics 
Evidently, from the data above, batch 12SSG-5CF (formulation 8) was considered an optimum 
formulation in terms of crushing strength, in vitro disintegration and wetting time followed by 
8SSG-5CF (formulation 7). These batches were selected for further evaluation which gives 
finally 4 formulations after incorporation of 10 %w/w non-coated and PGA-co-PDL/Eudragit 
MPs loaded IND in tablets as shown in Table 3.  
Crushing strength, wetting time, in vitro disintegration   
Crushing Strength: It was observed that by increasing the concentration of SSG from 8 to 12 
%w/w a non-significant (p> 0.05, ANOVA/ Tukey’s) higher increase in crushing force was 
required to break the tablets containing both non-coated and PGA-co-PDL/Eudragit MPs 
loaded IND. FDTs containing PGA-co-PDL/Eudragit MPs loaded IND compressed at 5 CF 
and containing 8 %w/w SSG (formulation 9) had a crushing force at 88.0±6.5 KN which was 
significantly (p<0.05. ANOVA/Tukey’s) higher than non-coated PGA-co-PDL MPs loaded 
IND (formulation 7) at 35.5±4.5 KN. Similar behaviour was also found with FDTs containing 
non-coated and PGA-co-PDL/Eudragit MPs and 12 %SSG as shown in Table 4. Formulations 
of MPs into tablets increased tablets tensile strength as compaction of smaller particles resulted 
larger surface area available for binding (Dolenc et al., 2009).  
Wetting Time: Addition of non-coated PGA-co-PDL MPs to FDTs did not significantly affect 
the wetting time compared to FDTs without MPs. However; FDTs containing PGA-co-
PDL/Eudragit MPs with 12 %SSG (Formulation 10) showed significantly (p<0.05, 
ANOVA/Tukey’s) higher wetting time (32.0 s) compared to non-coated PGA-co-PDL MPs 
(17.5 s, Formulation 8) compressed at the same compression force of 5 KN and containing 12 
%SSG. It was also found that formulation 9 showed the highest wetting time of 139.7±5.8 s as 
shown in Table 4. The delay in wetting for PGA-co-PDL/Eudragit particles could be attributed 
to the adherent properties of Eudragit and the high bonding of the produced tablets presented 
with a higher crushing force as mentioned earlier, which hinders liquid penetration into tablet 
especially at high compression force which (Marais et al., 2003).  
Disintegration Time: It was observed that PGA-co-PDL/Eudragit MPs (Formulations 9 & 10) 
increased significantly (p<0.05, ANOVA/Tukey’s) the disintegration time with both 8 and 12 
%SSG compared to non-coated PGA-co-PDL MPs (formulations 7 & 8). In addition tablets 
containing non-coated PGA-co-PDL MPs loaded IND (Formulation 8) showed significantly 
(p<0.05, ANOVA/Tukey’s) low disintegration time of 7.2±2.1 s using 12 %SSG compared to 
40.5±5.5 s with PGA-co-PDL/Eudragit MPs loaded IND (Formulation 10) as depicted in Table 
4. Similar trend was also found with Formulations 7 & 9 containing 8 %SSG. The European 
Pharmacopeia states that orodispersable tablet are required to disintegrate in less than 3 
minutes, hence all formulation pass this requirement (pharmacopoeia, 2002). The delay in the 
disintegration time for PGA-co-PDL/Eudragit MPs loaded IND could be possibly attributed to 
the adherent property of Eudragit which causing the particles to bind stronger therefore 
resulting in a slower disintegration time as well as the higher wetting time as mentioned 
previously (Chang and Hsiao, 1989). Moreover, they disintegrate in relatively short period of 
time capable of releasing the IND loaded PGA-co-PDL/Eudragit MPs in the mouth cavity to 
be readily swallowed into the GIT. 
3.6. Permeability and transport study 
Caco-2 cells were used in this study as a model of human intestinal absorption of drugs and 
other compounds ((van Breemen and Li, 2005)). Permeability of IND across Caco-2 
monolayers were tested in the apical to basolateral direction, and apparent permeability 
coefficients (Papp) were used to compare IND permeability between an IND control and 
treatments 1 and 4 (Table 5). Controls showed the greatest Papp value of 23.06± 3.56 x 10
-6 
cm/s. Papp values for treatment 1 were 13.95± 0.68 x 10
-6cm/s and treatment 4 were 13.27± 0.58 
x 10-6 cm/s, a drop of almost half. Reduction in Papp for treatments 1 and 4 were significant 
compared to IND control (p<0.05, ANOVA/Tukey’s), whilst differences in Papp between the 
two treatments were insignificant (p>0.05, ANOVA/Tukey’s). Papp values indicated medium 
to high permeability of IND and were intermediate of those previously reported for IND using 
Caco-2 models (ElShaer et al., 2014; Jin et al., 2014; Jung et al., 2006). Also, these results are 
in agreement with a previous report for famotidine loaded MPs and dexamethasone loaded NPs 
coated MPs transport across Caco-2 cell monolayers (Beck et al., 2007; Degim et al., 2005).  
 As observed in the in vitro drug release studies, we could demonstrate the influence of 
coating on the absorption of IND across Caco-2 cell monolayers. IND loaded PGA-co-
PDL/Eudragit MPs at ratio of 1:1:5 presented the lowest percentage of IND release after 360 
mins (24.78±2.26 %). Another possible explanation could be attributed to the effect of pH and 
acidity of the apical and basolateral layers across Caco-2 cell monolayers. In the case of IND, 
both the apical and basolateral layers had a pH value of 7.4 (DMEM, medium), which will 
facilitate the transport of free IND via passive diffusion in the apical to basolateral direction. 
However, non-coated and PGA-co-PDL/Eudragit MPs, the pH of the apical layer was 
measured and shifted to a slightly acidic value of 5.3. Also, Eudragit L100-55 is a methacrylic 
acid derivative which has the potential to decrease the pH of the apical layer while the 
basolateral pH was maintained at 7.3. This led to a reduction in the permeability of IND and 
conversion of the IND transport mechanism to active carrier mediated transport, which 
demonstrated saturation and competitive inhibition phenomena. Similarly, the effect of 
salicylic acid on the transport of IND across Caco-2 cell monolayers has previously been 
reported, with authors concluding that when the concentration of salicylic acid was increased 
from 25 µM to 33 µM, the IND Papp was reduced by 80% (Neuhoff et al., 2005).  
It must be emphasized that such a delay in IND absorption could further increase the 
advantages of encapsulation of IND in these PGA-co-PDL/Eudragit MPs. Among the major 
problems in the treatment of IBD is the necessity for administration of high doses of anti-
inflammatory drugs and the low residence time of these drugs in the gut due to rapid absorption 
and diarrhoea, a frequent symptom of IBD (Kawashima et al., 1993; Lamprecht et al., 2001; 
Lamprecht et al., 2004). Thus, the fabricated PGA-co-PDL/Eudragit MPs could combine 
controlled drug release and prolonged residence time of MPs at the site of action, thus 
decreasing the frequency of drug administration. Furthermore, the lowering in Papp could 
increase their biological importance through increased protection of the GIT mucosa, as in the 
case of diclofenac loaded nanocapsules coated MPs (Beck et al., 2006). In addition, no drop in 
cell integrity was noticed (p>0.05, ANOVA/Tukey’s) over the experimental period (from t=0 
to t=360 mins), with mean TEER values of 1822±68 and 1767±79 Ω.cm2 at the beginning and 
end of testing, respectively. TEER values for negative controls (treatments 2 and 3) were 
similarly maintained, suggesting that the MPs are non-toxic to the cells. Furthermore, it 
indicates non-paracellular route for drug absorption. It was reported by Borchard G et al. 
(Borchard et al., 1996), that a reduction of TEER value more than 50 % from the initial value 
could be indicative for tight junctions relaxations and establishment of paracellular transport. 
4. Conclusions 
From the data obtained in this study it can be concluded that IND loaded PGA-co-
PDL/Eudragit MPs delivered in the form of FDTs could be considered as a promising 
formulation for targeting IND to the colon. The prepared PGA-co-PDL/Eudragit MPs showed 
good encapsulation efficiency and IND loading, moreover, they were efficiently coated with 
Eudragit L100-55 via spray drying technique as demonstrated from DSC and PXRD studies. 
Moreover, PGA-co-PDL/Eudragit MPs showed a sustained release profile specifically at 
higher GIT pH. Furthermore, the optimum FDTs containing IND loaded PGA-co-
PDL/Eudragit MPs and 12 %SSG showed disintegration time and wetting of 40.5±5.5 s and 
32.0 s; respectively. In addition, the permeability of PGA-co-PDL/Eudragit MPs favoured 
transcellular pathway over paracellular route without affecting cell integrity, as indicated by 
little change in TEER value at end of permeability study. Moreover, they had a lower 
permeability compared with free IND, which could be beneficial in treatment of IBD.   
Spray-drying and tablet manufacture are techniques employed for large scale-production in the 
pharmaceutical industry. However, despite the promising results reported, the method of 
fabricating MPs is via the solvent emulsion evaporation technique, and there is possibility of 
the MPs size and encapsulation efficiency changing during scale-up. An alternative is to use 
microfluidic strategies, which allows control of process parameters enabling the fabrication of 
MPs of desired shape, size, and morphology and controlling encapsulation efficiency at the 
bench-scale to reproducible larger-scale production (Choi et al., 2017; Duncanson et al., 2012; 
Seo et al., 2015; Zhao, 2013). Furthermore, the advances in microfluidic systems such as 
multiple modules or parallelisation allows for scale-up and as technology improves, the cost 
will also be reduced ensuring more economical viable products for pharmaceutical companies 
and patients. 
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Fig. 1: The XRD pattern of (A) PGA-co-PDL; (B) Eudragit L100-55; (C) non-coated IND 
loaded PGA-co-PDL microparticles and (D) Eudragit coated IND loaded PGA-co-PDL 
microparticles (1:1.5 wt ratio). 
Fig. 2: DSC thermograms of (A) Indomethacin; (B) Eudragit L100-55; (C) IND loaded PGA-
co-PDL micrparticles; (D) Eudragit coated IND loaded PGA-co-PDL microparticles (1:0.5wt. 
ratio); (E) Eudragit coated IND loaded PGA-co-PDL microparticles (1:1wt. ratio) and (F) 
Eudragit coated IND loaded PGA-co-PDL microparticles (1:1.5wt ratio). 
Fig. 3: Scanning electron microscope images of  (A) spray dried blank Eudragit L100-55 
particles; (B) spray dried blank PGA-co-PDL particles; (C) spray dried Eudragit coated IND 
loaded PGA-co-PDL microparticles (1:0.5wt. ratio); (D) spray dried Eudragit coated IND 
loaded PGA-co-PDL microparticles (1:1wt. ratio) and (E) spray dried Eudragit coated IND 
loaded PGA-co-PDL microparticles (1:1.5wt ratio). Scale bar represents 50 µm for image (A) 
and 10 µm for images (B-E). 
Fig. 4: In vitro release study of IND from IND loaded PGA-co-PDL microparticles and spray 
dried Eudragit coated IND loaded PGA-co-PDL microparticles (1:0.5; 1:1 and 1:1.5 wt. ratios 
at pH 1.2, 5.5 and 6.8 for 2, 3 and 43 hrs, respectively, (n=3). 
Fig. 5: (A) The crushing strength (KN) of blank FDTs using different compression forces and 
Ac-Di-Sol as superdisintegrant, (n=10). (B) The crushing strength (KN) of blank FDTs using 
different compression forces and SSG as superdisintegrant, (n=10). (C) In vitro disintegration 
time (seconds) of blank FDTs containing either Ac-Di-Sol or SSG different concentrations and 
compressed at 5, 10 and 15 KN, (n=6). (D) The wetting time (seconds) for blank FDTs 
containing either Ac-Di-Sol or SSG different concentrations and compressed at 5, 10 and 15 
KN, (n=6) * Significantly different (p<0.05, ANOVA/Tukey’s) at 5 KN compared to 10 and 15 KN for FDTs containing Ac-Di-Sol, ** 
significantly different(p<0.05, ANOVA/Tukey’s) at 12% SSG compared to 5 and 8% at 5 KN compression force. # Significantly different 
(p<0.05, ANOVA/Tukey’s) at 5 KN compared to 10 and 15 KN for FDTs tablets containing different concentrations of either Ac-Di-Sol or 
SSG.  
 
  


 
  
 Table 1. The Superdisintegrant type and concentrations and the corresponding compression 
force 
 
 
 
 
                    KN, Kilonetwon; CF, Compression force; AC, Ac-Di-Sol; SSG, Sodium starch glycolate  
 
 
Compression 
Force (KN) 
Superdisintegrant type and Concentration (w/w) 
Ac-Di-
Sol 5%  
Ac-Di-
Sol 8%  
Ac-Di-Sol 
12%  
SSG 5%  SSG 8% SSG 12% 
5KN 5AC-5CF 8AC-5CF 12AC-
5CF 
5SSG-
5CF 
8SSG-
5CF 
12SSG-
5CF 
10KN 5AC-
10CF 
8AC-
10CF 
12AC-
10CF 
5SSG-
10CF 
8SSG-
10CF 
12SSG-
10CF 
15KN 5AC-
15CF 
8AC-
15CF 
12AC-
15CF 
5SSG-
15CF 
8SSG-
15CF 
12SSG-
15CF 
 Table 2. The composition of the different prepared blank FDTs 
 
 
 
 
 
 
 
              Diluent, lactose anhydrous; Lubricant, magnesium stearate 
 
 
Excipients (mg) 
Formulation 1 
(SSG) 
Formulation 2 
(SSG) 
Formulation 3 
(SSG) 
Formulation 4  
(Ac-Di-Sol) 
Formulation 5 
(Ac-Di-Sol) 
Formulation 6 
(Ac-Di-Sol) 
Superdisintegrant  10 16 24 10 16 24 
Diluent 188 182 174 188 182 174 
Lubricant 2 2 2 2 2 2 
Total  200 200 200 200 200 200 
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Table 3. The composition of FDTs containing non-coated and PGA-co-PDL-IND/Eudragit 
MPs and compressed at 5 KN compression force. 
 
Excipients (mg) Formulation 7 Formulation 
8 
Formulation 
9 
Formulation 10 
Superdisintegrant, 
SSG 
16 24 16 24 
MPs 20 
PGA-co-PDL 
20 
PGA-co-PDL 
20 
PGA-co-PDL 
Eudragit/ 
(1:1.5 wt/wt) 
20 
PGA-co-PDL 
Eudragit/ (1:1.5 
wt/wt) 
Diluent 162 154 162 154 
Lubricant 2 2 2 2 
Total 200 200 200 200 
Diluent, lactose anhydrous; Lubricant, magnesium stearate 
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Table 4. The crushing strength, wetting time and in vitro disintegration time for FDTs after 
MPs addition (mean ± SD, n=6) 
 
Formulation Crushing strength 
(KN) 
Wetting time 
(s) 
In vitro disintegration time 
(s) 
Formulation 7 35.5±4.5 16.3±1.2 19±3.2*** 
Formulation 8 42.0±3.2 17.5 7.2±2.1*** 
Formulation 9 88.0±6.5* 139.7±5.8 151±8.9 
Formulation 10 96.3±5.3 32.0±1.7** 40.5±5.5 
*Significantly higher crushing strength Vs Formulation 7;** significantly higher wetting time Vs Formulation 8; *** significantly lower 
disintegration time Vs Formulations 9 & 10.   
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Table 5. Papp vales for IND control and treatments 1 and 4 in the A-B direction across Caco-2 
monolayers at pH 7.4 in both compartments (mean ± SD, n=3) 
Treatment Papp (10-6 cm s-1) 
Control 23.06± 3.56 
1 13.95± 0.68* 
4 13.27± 0.58* 
      *Significant reduction in Papp for treatments 1 and 4 Vs IND control  
 
